Serum Oxidative Stress Marker Levels in Unmedicated and Medicated Patients with Schizophrenia
| Autor: | Xue-Song Li, Zhile Bai, Xi Chen, Yang Du, Guang-En Zheng, Guang-Yang Chen, Wen Deng, Ze-Xu Wei, Yong Cheng |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Side effect medicine.medical_treatment medicine.disease_cause Superoxide dismutase Lipid peroxidation 03 medical and health sciences Cellular and Molecular Neuroscience chemistry.chemical_compound 0302 clinical medicine Internal medicine Malondialdehyde mental disorders medicine Humans Antipsychotic chemistry.chemical_classification Glutathione Peroxidase biology business.industry Superoxide Dismutase Glutathione peroxidase General Medicine medicine.disease 030227 psychiatry Oxidative Stress Endocrinology chemistry Schizophrenia biology.protein Female business 030217 neurology & neurosurgery Oxidative stress Biomarkers Antipsychotic Agents |
| Zdroj: | Journal of molecular neuroscience : MN. 66(3) |
| ISSN: | 1559-1166 |
| Popis: | Oxidative stress has been suggested to be involved in schizophrenia, but studies have demonstrated inconsistent results on oxidative stress marker level/activity in patients with schizophrenia. In order to clarify the circulating oxidative stress marker level/activity in patients with schizophrenia, this study recruited 80 schizophrenia patients (40 first-episode, drug-free and 40 chronically medicated patients) and 80 controls to analyze serum activities of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and total antioxidant capacity (T-AOC), and levels of lipid peroxidation marker malondialdehyde (MDA) in schizophrenia patients, and whether they associate with the severity of the disease. We showed that only serum GSH-Px activity was significantly reduced in unmedicated patients with schizophrenia when compared with control subjects, whereas the other three analyzed oxidative stress markers did not show significant differences between cases and controls. Moreover, our results demonstrated that chronic medication increased GSH-Px activity and MDA levels in patients with schizophrenia, but reduced SOD activity in the patients. We also found that short-term antipsychotic treatments on the patients with schizophrenia reduced the SOD activity. Correlation analyses indicated that the oxidative stress marker activity/level is not significantly associated with the severity of schizophrenia, except that SOD level correlated with PANSS positive score significantly. Taken together, the data from the present study suggested that the dysfunctions of oxidative stress markers in patients with schizophrenia were mainly caused by antipsychotics, emphasizing increased oxidative stress as a potential side effect of antipsychotics on the patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink